Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10863
Title: | Molecular characterization of drug resistance in hepatitis B viruses isolated from patients with chronical infection in Turkey | Authors: | Asan, A. Sayan, M. Akhan, S. Koruk, S.T. Aygen, B. Sirmatel, F. Eraksoy, H. |
Keywords: | Antiviral Drug Resistance Chronic Hepatitis B HBsAg HBV Polymerase Hepatitis B Virus Sequence Analysis adefovir alanine aminotransferase aspartate aminotransferase hepatitis B surface antigen hepatitis B(e) antigen lamivudine peginterferon telbivudine tenofovir adult aged amino acid substitution Article enzyme linked immunosorbent assay female gene mutation gene sequence hepatitis B Hepatitis B virus Hepatitis B virus genotype D human major clinical study male prevalence real time polymerase chain reaction virus isolation virus load |
Publisher: | Kowsar Medical Publishing Company | Abstract: | Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy. Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hepatitis B (CHB) infection. Methods: Polymerase chain reaction (PCR) amplification and direct sequencing procedures were used to analyze mutations. The detected drug resistance mutations were divided into the nucleos(t)ide analogs primary, partial, and compensatory resistance groups. The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vaccine - escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin (HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitutions. Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary, partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8% (n = 184), respectively. Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for hepatitis B is of paramount importance to monitor and control the emerging resistance. © 2018, Hepatitis Monthly. | URI: | https://hdl.handle.net/11499/10863 https://doi.org/10.5812/hepatmon.12472 |
ISSN: | 1735-143X |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Molecular Characterization.pdf | 136.12 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
3
checked on Sep 30, 2024
WEB OF SCIENCETM
Citations
4
checked on Sep 24, 2024
Page view(s)
52
checked on Aug 24, 2024
Download(s)
22
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.